Notícias e Atividades da Kezar Life Sciences

Kezar Life Sciences é uma das ...

• Russell 3000;
• TOB Iconic 10,000.

Kezar Life Sciences é uma empresa listada sob o símbolo KZR (US).

Veja o organograma con seus 23 executivos principais

Biografias mais buscadas da Kezar Life Sciences

• Christopher Kirk, Director and Chief Executive Officer
• Elizabeth Garner, Director
• Micki Klearman, Director

Criar um alerta
para seguir os movimentos de executivos da Kezar Life Sciences.

Kezar Life Sciences possui 2.351 concorrentes concorrentes Eurofins (Luxemburgo), Lonza (Suíça) e Genus (Reino Unido).

Popular M&A news in Biotecnologia

• Transcarent and Accolade have merged  (publicado em 9 de abril de 2025)..
• Kashiv BioSciences acaba de anunciar uma arrecadação de fundos de 150 milhões de dólares. (publicado em 7 de abril de 2025).
• Atsena Therapeutics acaba de anunciar uma arrecadação de fundos de 150 milhões de dólares. (publicado em 4 de abril de 2025).

Outros contatos sugeridos na indústria do Biotecnologia

• Kristina Burow - Director da Scholar Rock
• Steven Gillis - Chairman of the Board da VBI Vaccines
• Ali Behbahani - Non-Executive Director da Adaptimmune Therapeutics

Saiba mais sobre a indústria do Biotecnologia

Últimos comunicados de imprensa de Kezar Life Sciences

• Kezar Life Sciences Announces Positive Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis (AIH) and Reports Fourth Quarter and Year End 2024 Financial Results | Kezar Life Scienc
• Kezar Life Sciences to Present Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis on March 25, 2025 | Kezar Life Sciences, Inc.
• Kezar Life Sciences to Present at Virtual KOL Event Hosted by William Blair on Zetomipzomib Clinical Development in Autoimmune Hepatitis and Provide a Safety Update from the PALIZADE Trial for Lupus Nephritis on February 27, 2025 | Kezar Life Sciences, In
• Kezar Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update | Kezar Life Sciences, Inc.
• Kezar Life Sciences Announces 1-for-10 Reverse Stock Split | Kezar Life Sciences, Inc.
• Kezar Board Unanimously Rejects Unsolicited Concentra Proposal and Adopts Limited Duration Stockholder Rights Plan | Kezar Life Sciences, Inc.
• Kezar Life Sciences Announces Positive IDMC Safety Review of PORTOLA Trial of Zetomipzomib in Patients with Autoimmune Hepatitis and Provides PALIZADE Update | Kezar Life Sciences, Inc.
• Kezar Confirms Receipt of Unsolicited, Non-Binding Acquisition Proposal | Kezar Life Sciences, Inc.
• Kezar Life Sciences Announces Clinical Hold of Zetomipzomib IND for Treatment of Lupus Nephritis | Kezar Life Sciences, Inc.
• Kezar Life Sciences Announces Cessation of Enrollment and Dosing in the Phase 2b PALIZADE Trial of Zetomipzomib in Active Lupus Nephritis Patients | Kezar Life Sciences, Inc.
• View more press releases Close

Redes sociais sobre Kezar Life Sciences

• Kezar Life Sciences na Wikipedia, Google News e Yahoo Finance
• Kezar Life Sciences na LinkedIn, Twitter e YouTube